| Abstract: | Δ6‐desaturase is located in a pivotal position in the metabolism of essential fatty acids (EFA). Various methods have been used to estimate Δ6‐desaturase activity, including the assessment of: (i) tissue fatty acid compositions (and associated product/precursor ratios), (ii) Δ6‐desaturase activities ex vivo, and (iii) isotopically labelled linoleic acid metabolism in vivo. This review critically examines these methods and considers their appropriateness and reliability in assessing linoleic acid metabolism in diabetes and cardiovascular disease. In general, there was a good agreement between the three methods and the effect of experimental diabetes on linoleic acid metabolism. In humans, however, the effect of diabetes on tissue fatty acid composition was inconsistent, and there was a paucity of data on linoleic acid metabolism ex vivo and in vivo. The inconsistency in human fatty acid compositional data may relate to variable and uncontrolled intakes of linoleic acid and its n‐6 metabolites, but also to a less extreme insulin deficiency as studied in animals. Risk markers for cardiovascular disease generally reduced rat liver Δ6‐desaturase activity ex vivo. This was not, however, reflected in tissue fatty acid compositions in these controlled studies. Linoleic acid metabolism, as determined by tissue fatty acid composition in humans, is reduced in cardiovascular disease; however, the omnivorous dietary patterns and decreased linoleic acid intakes make this conclusion potentially unreliable. Few stable‐isotope studies have been conducted on the effect of cardiovascular risk markers on linoleic acid metabolism, and there is a requirement for this type of work to be standardised to facilitate inter‐study comparisons. These studies may eventually help optimise EFA intake in health and disease conditions. |
